D-219-2013 Class III Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-219-2013 was initiated by Pfizer Inc. on Nov 26, 2012 and is designated Class III. Reason for recall: Lack of Assurance of Sterility; potential that a low level of endotoxins may be present in the diluent vials. The recall status is terminated (terminated Mar 31, 2015). Affected quantity: 10920 kits.

Recall details

Product Type
Drugs
Report Date
Apr 3, 2013
Initiation Date
Nov 26, 2012
Termination Date
Mar 31, 2015
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
10920 kits

Product description

TORISEL Kit (temsirolimus) injection, 25 mg/mL, CONCENTRATED, Rx Only, Packaged in a carton containing 1 vial TORISEL injection and 1 vial DILUENT for TORISEL, Distributed by Wyeth Pharmaceuticals Inc., A subsidiary of Pfizer Inc., Philadelphia, PA --- NDC 0008-1179-01

Reason for recall

Lack of Assurance of Sterility; potential that a low level of endotoxins may be present in the diluent vials.

Distribution pattern

Nationwide

Code information

Lots P00025A; P00027B

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-219-2013
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-219-2013. Report a data issue: hello@regdatalab.com.